+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Excessive Daytime Sleepiness (EDS) - Epidemiology Forecast to 2030

  • ID: 5238587
  • Report
  • January 2021
  • Region: Global
  • 80 pages
  • DelveInsight
1 of 2
This ‘Excessive Daytime Sleepiness (EDS)-Epidemiology Forecast-2030’ report delivers an in-depth understanding of the EDS, historical and forecasted epidemiology as well as the EDS trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Excessive Daytime Sleepiness (EDS) Disease Understanding

Excessive daytime sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. EDS is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. EDS is also commonly associated with social and economic consequences thus constituting a significant public health problem.

Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of EDS and Total Diagnosed Prevalent Cases of EDS in Different Disorder scenario of EDS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Excessive Daytime Sleepiness (EDS) Detailed Epidemiology Segmentation
  • In the epidemiology report, the research team have considered major indications in which EDS occurs, such as Parkinson’s disease (PD), Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea (OSA), and Bipolar Disorder.
  • The total diagnosed prevalent population of EDS in these five disorders in the 7MM was estimated to be 6,295,782 in 2017.
  • The total diagnosed prevalent cases of EDS in the US were 2,960,518 in 2017.
  • In the US, the majority of the cases of EDS are found in OSA and Bipolar disorder, followed by Parkinson's Disease, Narcolepsy, and Idiopathic Hypersomnia.
  • Among the European countries, Germany had the highest diagnosed prevalent population of EDS with 590,827 cases, followed by France which had a diagnosed prevalent population of 487,146 in 2017. On the other hand, Italy had the lowest diagnosed prevalent population.
  • The total diagnosed prevalent cases of EDS in Japan were 1,410,155 in 2017. The highest cases were estimated in OSA, followed by Bipolar Disorder. There were about 1,177,957 EDS cases diagnosed in OSA, followed by 149,322 EDS cases in Bipolar Disorder. The diagnosed EDS cases in other disorders were 47,419 in Narcolepsy, 1,600 in IH, and 33,857 in PD.
Scope of the Report
  • The report covers the descriptive overview of EDS, explaining its causes and diagnosis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of EDS.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Cases of EDS and Total Diagnosed Prevalent Cases of EDS in Different Disorder.
Report Highlights
  • 11-Year Forecast of EDS
  • 7MM Coverage
  • Total Diagnosed Prevalent Cases of EDS
  • Total Diagnosed Prevalent Cases of EDS in Different Disorder
Key Questions Answered
  • What are the disease risk, burdens, and unmet needs of EDS?
  • What is the historical EDS patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of EDS at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EDS?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of EDS during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to Buy

The EDS report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM EDS epidemiology forecast.
  • The EDS epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The EDS epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Executive Summary of Excessive Daytime Sleepiness (EDS)

3. Excessive Daytime Sleepiness (EDS) Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of Excessive Daytime Sleepiness (EDS) in 2017
3.2. Epidemiology Share (%) Distribution of Excessive Daytime Sleepiness (EDS) in 2030

4. Excessive Daytime Sleepiness (EDS): Disease Background and Overview
4.1. Introduction
4.2. Causes of EDS
4.3. Classification
4.4. Diagnosis
4.5. Diagnostic Algorithm
4.6. Diagnosis Guidelines
4.7. Clinical Approach in the Diagnosis of EDS
4.7.1. Measurement of Sleepiness
4.7.2. Objective Measures of Daytime Sleepiness

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology Methodology
5.3. 7MM Total Diagnosed Prevalent Population of Excessive daytime sleepiness (EDS)

6. Country Wise-Epidemiology of Excessive daytime sleepiness (EDS)
6.1. United States Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Diagnosed Prevalent Cases of Excessive daytime sleepiness (EDS) in the US
6.1.3. Total Diagnosed Prevalent Cases of EDS in different disorder in the US
6.2. EU5 Epidemiology
6.2.1. Germany
6.2.1.1. Assumptions and Rationale
6.2.1.2. Total Diagnosed Prevalent Cases of Excessive daytime sleepiness (EDS) in Germany
6.2.1.3. Total Diagnosed Prevalent Cases of EDS in different disorder in Germany
6.2.2. France
6.2.2.1. Assumptions and Rationale
6.2.2.2. Total Diagnosed Prevalent Cases of EDS in France
6.2.2.3. Total Diagnosed Prevalent Cases of EDS in different disorder in France
6.2.3. Italy
6.2.3.1. Assumptions and Rationale
6.2.3.2. Total Diagnosed Prevalent Cases of EDS in Italy
6.2.3.3. Total Diagnosed Prevalent Cases of EDS in different disorder in Italy
6.2.4. Spain
6.2.4.1. Assumptions and Rationale
6.2.4.2. Total Diagnosed Prevalent Cases of EDS in Spain
6.2.4.3. Total Diagnosed Prevalent Cases of EDS in different disorder in Spain
6.2.5. United Kingdom
6.2.5.1. Assumptions and Rationale
6.2.5.2. Total Diagnosed Prevalent Cases of EDS in the United Kingdom
6.2.5.3. Total Diagnosed Prevalent Cases of EDS in different disorder in the United Kingdom
6.3. Japan Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Diagnosed Prevalent Cases of EDS in Japan
6.3.3. Total Diagnosed Prevalent Cases of EDS in different disorder in Japan

7. Appendix
7.1. Bibliography
7.2. Report Methodology

8. Publisher Capabilities

9. Disclaimer

10. About the Publisher

List of Tables
Table 1 Summary of Excessive Daytime Sleepiness (EDS), Epidemiology and Key Events (2017-2030)
Table 2 Common causes or contributors to Excessive Daytime Sleepiness
Table 3 ESS Scores
Table 4 Diagnostic criteria for narcolepsy types 1 and 2 (adapted from ICSD-3)
Table 5 Diagnostic criteria for idiopathic hypersomnia (adapted from ICSD-3)
Table 6 Total Diagnosed Prevalent Population of ED) in the 7MM (2017-2030)
Table 7 Total Diagnosed Prevalent Cases of EDS in the US (2017-2030)
Table 8 Total Diagnosed Prevalent Cases of EDS in different disorder in the US (2017-2030)
Table 9 Total Diagnosed Prevalent Cases of EDS in Germany (2017-2030)
Table 10 Total Diagnosed Prevalent Cases of EDS in different disorder in Germany (2017-2030)
Table 11 Total Diagnosed Prevalent Cases of EDS in France (2017-2030)
Table 12 Total Diagnosed Prevalent Cases of EDS in different disorder in France (2017-2030)
Table 13 Total Diagnosed Prevalent Cases of EDS in Italy (2017-2030)
Table 14 Total Diagnosed Prevalent Cases of EDS in different disorder in Italy (2017-2030)
Table 15 Total Diagnosed Prevalent Cases of EDS in Spain (2017-2030)
Table 16 Total Diagnosed Prevalent Cases of EDS in different disorder in Spain (2017-2030)
Table 17 Total Diagnosed Prevalent Cases of EDS in the UK (2017-2030)
Table 18 Total Diagnosed Prevalent Cases of EDS in different disorder in the UK (2017-2030)
Table 19 Total Diagnosed Prevalent Cases of EDS in Japan (2017-2030)
Table 20 Total Diagnosed Prevalent Cases of EDS in different disorder in Japan (2017-2030)

List of Figures
Figure 1 Causes of excessive daytime sleepiness
Figure 2 Suggested clinical algorithm for the diagnosis of suspected OSA, narcolepsy, or other sleep disorders based on symptoms of excessive daytime sleepiness
Figure 3 Clinical approach to excessive daytime sleepiness
Figure 4 Total Diagnosed Prevalent Population of EDS in the 7MM (2017-2030)
Figure 5 Total Diagnosed Prevalent Cases of EDS in the US (2017-2030)
Figure 6 Total Diagnosed Prevalent Cases of EDS in different disorder in the US (2017-2030)
Figure 7 Total Diagnosed Prevalent Cases of EDS in Germany (2017-2030)
Figure 8 Total Diagnosed Prevalent Cases of EDS in different disorder in Germany (2017-2030)
Figure 9 Total Diagnosed Prevalent Cases of EDS in France (2017-2030)
Figure 10 Total Diagnosed Prevalent Cases of EDS in different disorder in France (2017-2030)
Figure 11 Total Diagnosed Prevalent Cases of EDS in Italy (2017-2030)
Figure 12 Total Diagnosed Prevalent Cases of EDS in different disorder in Italy (2017-2030)
Figure 13 Total Diagnosed Prevalent Cases of EDS in Spain (2017-2030)
Figure 14 Total Diagnosed Prevalent Cases of EDS in different disorder in Spain (2017-2030)
Figure 15 Total Diagnosed Prevalent Cases of EDS in the UK (2017-2030)
Figure 16 Total Diagnosed Prevalent Cases of EDS in different disorder in the UK (2017-2030)
Figure 17 Total Diagnosed Prevalent Cases of EDS in Japan (2017-2030)
Figure 18 Total Diagnosed Prevalent Cases of EDS in different disorder in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll